Welcome to our dedicated page for Enliven Therapeutics SEC filings (Ticker: ELVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enliven Therapeutics, Inc. (Nasdaq: ELVN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Enliven files a range of documents with the U.S. Securities and Exchange Commission (SEC), including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K describing material events.
For Enliven, Form 8-K filings are particularly relevant to investors monitoring clinical-stage and corporate milestones. Recent 8-Ks have covered topics such as quarterly financial results, leadership changes including the appointment of a new President and Chief Executive Officer, the adoption of the 2025 Inducement Equity Incentive Plan, and related compensatory arrangements. Amendments on Form 8-K/A may be used to correct or update previously furnished information, such as earnings press releases.
Periodic reports on Form 10-K and Form 10-Q (referenced in Enliven’s press releases) contain more detailed information on research and development expenses, general and administrative costs, net loss, cash, cash equivalents and marketable securities, as well as risk factors and management’s discussion and analysis. These filings help contextualize the company’s ability to fund the ENABLE Phase 1 trial of ELVN-001 and potential future studies.
On Stock Titan, users can review Enliven’s SEC filings alongside AI-powered summaries that explain key points in accessible language, highlight important sections, and help interpret complex disclosures. Real-time updates from EDGAR allow quick access to new filings, while specialized forms such as Form 4 (when available) can be used to track insider equity transactions. This page is a practical starting point for understanding Enliven’s regulatory history, financial reporting, equity plans and material corporate events related to its precision oncology programs.
Enliven Therapeutics director Joseph Lyssikatos reported proposed sales of common stock under a Form 144 notice. The filing lists 25,000 shares associated with Jefferies as the broker and multiple past dispositions totaling 130,000 shares across February–March 2026 with aggregate proceeds shown per trade. The filing documents routine resale activity by an insider; timing and additional proceeds treatment are shown by the listed trade dates.
Enliven Therapeutics, Inc. is asking stockholders to vote on five proposals at its 2026 virtual annual meeting on June 9, 2026. Items include electing two Class III directors, ratifying Deloitte as auditor, and an advisory “Say‑on‑Pay” vote plus its future frequency.
A key proposal seeks to amend the Restated Certificate to increase authorized common stock from 100,000,000 to 200,000,000 shares, mainly to ensure sufficient capacity for future issuances. As of April 10, 2026, there were 60,895,009 common shares outstanding and entitled to vote.
Enliven Therapeutics chief medical officer Helen Louise Collins exercised stock options and sold shares in a pre-planned set of trades. On April 17, 2026, she exercised options to acquire 5,000 shares of common stock at $2.48 per share, then sold 5,000 shares in open-market transactions at weighted average prices around $45.81–$48.06, all under a Rule 10b5-1 trading plan adopted on October 19, 2025. After these transactions, she directly held 25,000 shares of Enliven common stock.
Enliven Therapeutics is soliciting proxies for its 2026 virtual Annual Meeting to be held June 9, 2026. Key items: election of two Class III directors, ratification of Deloitte as auditor, a proposal to increase authorized common stock, and advisory votes on executive pay and frequency. The Record Date is April 10, 2026 and 60,895,009 shares were outstanding as of that date.
Enliven Therapeutics submitted a Form 144 disclosing a proposed sale of 25,000 shares of Common Stock through Jefferies LLC, with an aggregate value listed as $914,750 and an entry date of 03/31/2026 on Nasdaq.
The filing also lists recent sales by Joseph Lyssikatos: 41,302 shares on 01/08/2026 for $993,437.48 and 91,198 shares on 01/09/2026 for $2,482,579.19, plus several other dispositions in January–February 2026.
Andrew Phillips files a Form 144 proposing sale of 26,035 shares of Common Stock. The filing shows 26,035 shares to be sold via a Stock Option Exercise on 03/31/2026 with cash proceeds to the issuer. The notice also lists prior sales of 21,844 and 1,520 shares on 02/02/2026 and 01/22/2026, respectively.
Enliven Therapeutics’ chief medical officer Helen Louise Collins exercised stock options and sold shares in a planned transaction. She exercised options for 40,000 shares of common stock at an exercise price of $2.48 per share and sold 40,000 shares at a weighted average price of $35.1006 per share. The filing states these trades were made under a Rule 10b5-1 trading plan adopted on October 19, 2025, indicating they were pre-scheduled. Following the transactions, Collins directly owns 25,000 shares of common stock and continues to hold 136,268 equity awards, including fully vested options and RSUs.
Enliven Therapeutics, Inc. filed a Section 144 notice reporting proposed and recent sales of Common Stock by an affiliate through Jefferies LLC.
The filing lists a proposed sale of 45,000 shares with a related value of $1,401,750.00 and trade/broker details noting Nasdaq and a filing date of 03/25/2026. The filing also discloses prior sales by Helen Collins of 45,000, 29,871, 10,129, and 5,000 shares on 02/17/2026, 03/09/2026, 03/10/2026, and 03/17/2026 respectively, with the dollar amounts shown for each transaction.
Enliven Therapeutics filed a Form 144 to sell 100,000 common shares. The notice lists these as founder shares with Jefferies LLC as broker and an intended sale on 03/24/2026 on Nasdaq.
The filing also discloses a prior sale of 48,300 shares by Anish Patel on 01/09/2026 for $1,351,761.47. The filing presents the proposed sale quantity and a recent disposition by an insider.